HORMONE RELATED MALIGNANCIES PROGRAM

描述：（申请人的描述）激素相关的目标 癌症计划旨在降低癌症的发病率和死亡率 生殖道肿瘤和内分泌系统的其他肿瘤， 诊断、预防和治疗。这些目标是通过促进 基础、临床和人口科学家之间的研究合作， 以及不同研究领域的科学家之间的交流。纲领性 促进互动的活动包括每周一次的研究研讨会系列; 每周乳腺癌、前列腺癌和妇科癌症临床会议;每年 小型对称会议;以及半年一次的重点小组会议。主实验室 该计划的研究主题是研究核和其他激素 作为治疗靶点的受体和细胞周期信号转导途径 和动物模型中的肿瘤发展研究。主要临床活动 该计划的重点是对乳腺癌患者进行高剂量化疗， 造血干细胞支持，乳腺和前列腺筛查研究 癌症以及前列腺癌和妇科癌症治疗研究。的数量 研究者发起的试验和这些试验的累积增加， 最后一次审查。这个项目是通过将以前的基础科学 计划，激素和癌症，与乳腺癌的临床计划， 前列腺癌和妇科癌症的疾病焦点组。dean医生 爱德华兹，乳腺癌计划的前共同领导人，成为了整体 1999年任项目负责人。他是由工作人员调查员加里米勒，医学博士， 博士和Elizabeth J. Shpall，MD。每个疾病领域（乳腺癌， 前列腺癌、妇科癌症和内分泌癌）继续保持 除了每周合并的临床会议之外， 科学研讨会系列来自四个重点领域的成员分别选择 这些研讨会以及小型研讨会的发言人和主题。这位34 常规项目成员和7名助理来自7个部门， 每年超过600万美元的直接成本研究和培训支持， 其中包括来自NCI的200多万美元和来自癌症的300万美元 社.乳腺癌联合培训补助金已提交， 程序员（D。Edwards，PI）。未来的计划包括增加临床 乳腺癌和前列腺癌的招募，所有领域的基本招募， 提交联合计划项目和SPORE申请。

Description: (Applicant's Description) The goal of the Hormone Related Malignancies Program is to lower the incidence and mortality rates of cancers of the reproductive tract and other tumors of the endocrine system by improved diagnosis, prevention, and therapy. These goals are achieved by facilitating research collaborations between basic, clinical, and population scientists, and between scientists with different research disciplines. Programmatic activities to stimulate interactions include a weekly research seminar series; weekly breast, prostate, and Gyn cancer clinical conferences; annual minisymposium; and semi-annual focus group meetings. The main laboratory research themes of the Program are study of nuclear and other hormone receptors and cell-cycle signal transduction pathways as therapeutic targets and tumor development studies in animal models. The main clinical activities of the program are high-dose chemotherapy of breast cancer patients with hematopoietic stem cell support, screening studies in both breast and prostate cancer, and prostate and Gyn cancer therapeutic studies. The number of investigator initiated trials and accrual to these trials have increased since the last review. This program evolved by merging the former basic science program, Hormones and Cancer, with the clinical program in Breast Cancer and the disease focus groups in prostate cancer and gynecologic cancers. Dr. Dean Edwards, former co-leader of the Breast Cancer program, became the overall program leader in 1999. He is assisted by staff investigators Gary Miller, MD, PhD, and Elizabeth J. Shpall, MD. Each of the disease areas (Breast Cancer, Prostate Cancer, Gyn Cancers, and Endocrine Cancers) continues to hold separate weekly clinical conferences in addition to the combined weekly scientific seminar series. Members from each of the four focus areas select the speakers and topics for these seminars as well as the minisymposia. The 34 regular program members and 7 associates come from seven departments and have more than $6 million in annual direct cost research and training support, including more than $2 million from the NCI and $3 million from cancer agencies. A joint training grant in breast cancer has been submitted by program members (D. Edwards, PI). Future plans include additional clinical recruitments in breast and prostate cancers, basic recruitments in all areas, submission of joint program projects, and a SPORE application.